European Expansion EU MDR approved CE-marked INT200 enables European market entry for the INTERCEPT Blood System. Target EU blood centers and hospitals with bundled equipment, disposables, and ongoing service contracts to accelerate adoption.

Leadership Change A forthcoming leadership transition with Vivek Jayaraman becoming CEO in July 2026 presents an opening to align on procurement cycles, pricing, and regional growth plans with the new leadership.

Growth Potential Cerus operates with lean headcount and mid-sized revenue, offering clear opportunities for multi-year enterprise deals, expanded service offerings, and geographic expansion into Europe and other markets.

Tech Enablement With a tech stack including AWS and Oracle ERP, there is an opportunity to propose cloud-connected device monitoring, LIS/EMR integration, and analytics-driven service programs to improve uptime and compliance.

Transfusion Focus Active participation in industry events such as AABB creates openings for training, accreditation support, and co-marketing partnerships to drive adoption of INTERCEPT solutions with INT200.